In in vitro models of non alcoholic fatty liver disease (NAFLD), the hepatic manifestation of obesity, overexpression of macroH2A1.1 led to a reduced lipid accumulation, while macroH2A1.2 overexpression yielded opposite effects24–26. This evidence concerns the gene MACROH2A1 and metabolic dysfunction-associated steatotic liver disease.